Skip to main content

Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks after Initiation of Treatment

CBE ID
0398
1.4 Project
Infectious Disease
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Full Year 2016
Is Under Review
No
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative hepatitis C Virus (HCV) ribonucleic acid (RNA) testing was performed between 4-12 weeks after the initiation of antiviral treatment

    • 1.14 Numerator

      Patients for whom quantitative HCV RNA testing was performed at no greater than 12 weeks from the initiation of antiviral treatment

    • 1.15 Denominator

      All patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment

    • Exclusions

      Documentation of medical reason(s) for not performing quantitative HCV RNA testing between 4-12 weeks after the initiation of antiviral treatment

      Hepatitis C quantitative RNA testing not performed between 4-12 weeks after the initiation of antiviral treatment for documented reason(s) (e.g., patients whose treatment was discontinued during the testing period prior to testing, other medical reasons, patient declined, other patient reasons)

      Clinician documented that patient is not an eligible candidate for quantitative RNA testing; patient not receiving antiviral treatment for Hepatitis C.

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Infectious Disease Project 2016-2017
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      American Gastroenterological Association
      Steward Organization POC Email
      [email protected]
      Steward Organization Copyright

      The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

      The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

      Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or American Gastroenterological Association (AGA). Neither the AMA, AGA, PCPI, nor its members shall be responsible for any use of the Measures.

      The AMA’s and PCPI’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. AGA is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of June 30, 2014.

      AGA encourages use of the Measures by other health care professionals, where appropriate.

      THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

      © 2014 American Medical Association and American Gastroenterological Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

      Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, AGA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

      CPT® contained in the Measures specifications is copyright 2004-2014 American Medical Association. LOINC® copyright 2004-2013 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2013 College of American Pathologists. All Rights Reserved.